Regeneron Pharmaceuticals said on Monday its experimental gene therapy showed improved hearing in 10 of 11 children between ...
Pfizer said on Thursday it will stop global development and commercialization of its hemophilia gene therapy, Beqvez, citing ...
In the phase 1/2 INSPIRE DUCHENNE trial, interim data showed an average microdystrophin expression of 110% among participants ...
ZME Science on MSN9h
Doctors Restore Sight in Blind Children with Groundbreaking Gene TherapyA single injection of a healthy gene allowed blind children to recognize objects, shapes, and even read — offering hope for ...
Fuse Vectors has raised $5.2 million of funding as it moves closer to commercialising its innovative new approach to ...
An experimental trial of gene therapy has helped four toddlers - born with one of the most severe forms of childhood ...
Ten of 11 children born with a rare form of congenital hearing loss experienced improvements after receiving the company’s ...
PRGN-2012—which Precigen has begun to call by its generic name of zopapogene imadenovec—is a gene therapy designed to elicit immune responses directed against cells infected with human papillomavirus ...
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results ...
OTO, is one of several early-stage gene therapies being developed to treat relatively straight-forward causes of genetic ...
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez. | ...
Researchers from the NIHR Moorfields Biomedical Research Centre and University College London have found that gene therapy improved visual acuity and preserved retinal structure in young children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback